The first objective of cancer research is the acquisition of a full understanding of cancer causation in the hope that discovery of causes will lead to knowledge of cure. Until this objective can be reached, however, it is imperative that we, as physicians, make use of all possible means by which a preclinical stage of cancer may be recognized. The tremendous strides made in the past decade in the recognition of preclinical cancer of the cervix1 have provided the stimulus to explore other organs, i. e., to determine the possibility that cytological methods, properly applied, may enable the recognition of cancer in these tissues before the stage of symptoms and clinical carcinoma. We have studied the prostate using cytology as an investigative tool, and our results2 indicate that preclinical cancer of the prostate is a recognizable entity when this valuable technique is effectively applied.
Preclinical cancer of the
Gunn SA, Ayre JE. THE ROLE OF CYTODIAGNOSIS IN PRECLINICAL CANCER OF THE PROSTATE. JAMA. 1955;158(7):548–551. doi:10.1001/jama.1955.02960070024007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: